Exabis Library
Welcome to the e-CCO Library!
DOP52: Development of a host-microbe interaction workflow to reveal the cell- and condition-specific effects of a commensal bacteria upon IBD
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP52: Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP52: Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP52: Reduction in inflammatory biomarkers in a phase 2 study of mirikizumab in patients with moderately-to-severely active ulcerative colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP52: Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP52: The faecal bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn's disease and the modifying effects of exclusive enteral nutrition and re-introduction of habitual diet
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP52: The faecal bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn’s disease and the modifying effects of exclusive enteral nutrition and re-introduction of habitual diet
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP52: The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s Disease or Ulcerative Colitis reflects the respective disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP52: The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s Disease or Ulcerative Colitis reflects the respective disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP53 PTPN2 and TiO2 in the pathogenesis of inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP53: Clinical, Endoscopic, Histologic and Biomarker Activity Following Treatment with the Gut-Selective, pan-JAK Inhibitor TD-1473 in Moderately-to-Severely Active Ulcerative Colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP53: Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP53: Community types of the human gut virome are associated with endoscopic outcome in UC patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP53: Community types of the human gut virome are associated with endoscopic outcome in UC patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP53: In-depth characterisation of the serum antibody epitope repertoire in Inflammatory Bowel Disease by high-throughput phage-displayed immunoprecipitation sequencing
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP53: Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP53: Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP54 Integrated network analysis using patient-specific single-nucleotide polymorphism profiles uncovers new pathways involved in ulcerative colitis pathogenesis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP54: Efficacy and safety of ustekinumab through week 16 in patients with moderate to severe ulcerative colitis randomised to ustekinumab: Results from the UNIFI induction trial
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP54: Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM